

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Angiogenix, Inc.	06/06/2007

RECEIVING PARTY DATA

Name:	Palmetto Medical, LLC
Street Address:	7 Coach Road
City:	Lexington
State/Country:	MASSACHUSETTS
Postal Code:	02420

PROPERTY NUMBERS Total: 23

Property Type	Number
Patent Number:	5543430
PCT Number:	US9512780
Patent Number:	5767160
Patent Number:	5968983
PCT Number:	US9807427
Patent Number:	6465516
Application Number:	09419517
Application Number:	10912717
Patent Number:	6239172
PCT Number:	US0000399
Patent Number:	6425881
Application Number:	10207399
Application Number:	10763309
PCT Number:	US0010298
Application Number:	09420816

CH \$920.00 5543430

Application Number:	10269847
PCT Number:	US0041304
Application Number:	60118903
Application Number:	09497721
PCT Number:	US0002798
Application Number:	09605559
Application Number:	10258633
PCT Number:	US0120887

CORRESPONDENCE DATA

Fax Number: (617)832-7000
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 617-832-1000
Email: lsimoglou@foleyhoag.com
Correspondent Name: Foley Hoag LLP
Address Line 1: 155 Seaport Blvd.
Address Line 4: Boston, MASSACHUSETTS 02210-2600

ATTORNEY DOCKET NUMBER:	27404-2
NAME OF SUBMITTER:	Robert W. Gauthier

Total Attachments: 5
source=Patent Assignment Exhibit#page1.tif
source=Patent Assignment Exhibit#page2.tif
source=Patent Assignment Exhibit#page3.tif
source=Patent Assignment Exhibit#page4.tif
source=Patent Assignment Exhibit#page5.tif

APPENDIX B

Form of

ASSIGNMENT

WHEREAS Angiogenix, Inc., having an address of 500 Airport Boulevard, Suite 100, Burlingame, CA 94010, (hereinafter the "Assignor") is the owner by assignment of the patents and patent applications listed on Exhibit A attached hereto (the "Patents").

AND WHEREAS, Palmetto Medical, LLC, having an address of 7 Coach Road, Lexington, MA 02420 (hereinafter the "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Patents and in and to any and all Letters Patent of the United States and foreign countries that may be obtained therefrom;

NOW, THEREFORE, for good and valuable consideration, the receipt for and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, transfer and set over unto Assignee, its legal representatives, successors, and assigns, the entire right, title and interest in and to said invention as set forth in the Patents, including any future utility application which claims priority from any Patent, continuations, continuations-in-part, divisions, reissues, re-examinations or extensions thereof, and in and to any and all patents of the United States and foreign countries which may be issued for said Patents, and including all rights to sue and recover damages for past infringements thereof or thereon;

UPON SAID CONSIDERATION, Assignor does hereby agree with the said Assignee that Assignor will not execute any writing or do any act whatsoever conflicting with these presents, and that Assignor will, at any time upon request, without further or additional consideration but at the expense of said Assignee, execute such additional assignments and other writings and do such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and render all necessary assistance in making application for or obtaining original, divisional, continuations, reexamined, reissued, or extended Letters Patent of the United States or of any and all foreign countries on said invention, and in enforcing any rights or chooses in action accruing as a result of such applications or patents, by giving testimony in any proceedings or transactions involving such applications or patents, and by executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of the assigns and legal representatives of Assignor and Assignee;

The undersigned hereby grant the firm of FOLEY HOAG LLP the power to insert on this Assignment any further identification, including the application number and filing date, which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

AND Assignor requests the Commissioner of Patents and Trademarks to issue any Letters Patent of the United States that may be issued for said Patents to said Assignee, its legal representatives, successors or assigns, as the sole owner of the entire right, title and interest in and to said patent and the invention covered thereby.

Date: 06 June, 2007

By: Edmon R. Jennings
 Name: Edmon R. Jennings
 Title: President's CEO

LEGALIZATION

STATE OF OREGON)
) SS:
Benton County)

On this 6th day of JUNE, 2007, before me personally appeared Edmon Jennings, to me known to be the person named in and who executed the above instrument, and acknowledged to me that he/she executed the same for the uses and purposes therein set forth.

SEAL

Ronald J. Motlok
 Notary Public

My commission expires August 2, 2008




Exhibit A to Patent Assignment

PATENTS AND PATENT APPLICATIONS

<u>COUNTRY</u>	<u>APPLICATION /PATENT NUMBER</u>	<u>TITLE</u>	<u>FILING DATE</u>
U.S.	5,543,430	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/1994
PCT	PCT/US95/12780	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Australia	705002	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Austria	E287.212	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Belgium	0784429	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Canada	2201784	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Denmark	0784429	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
EP	0784429	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
EP	04014650.8	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
France	0784429	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Germany	69533940.0	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Greece	0784429	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Ireland	0784429	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Italy	0784429	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Japan	8-512652	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Luxembourg	0784429	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Mexico	227678	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Netherlands	0784429	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Portugal	0784429	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Spain	0784429	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Sweden	0784429	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
Switzerland	0784429	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95
United Kingdom	0784429	Method and Formulation of Stimulating Nitric Oxide Synthesis	10/05/95

U.S.	5,767,160	Method and Formulation of Stimulating Nitric Oxide Synthesis	08/05/96
U.S.	5,968,983	Method and Formulation for Treating Vascular Disease	04/10/97
PCT	PCT/US98/07427	Method and Formulation for Treating Vascular Disease	04/10/98
Australia	744813	Method and Formulation for Treating Vascular Disease	04/10/98
Canada	2286671	Method and Formulation for Treating Vascular Disease	04/10/98
EP	98918177.1	Method and Formulation for Treating Vascular Disease	04/10/98
Japan	10-543200	Method and Formulation for Treating Vascular Disease	04/10/98
Mexico	9909243	Method and Formulation for Treating Vascular Disease	04/10/98
U.S.	6,465,516	Method of Stimulating Nitric Oxide Synthase	10/18/99
U.S.	09/419,517	Method and Formulation for Treating Vascular Disease	10/18/99
U.S.	10/912,717	Method and Formulation for Treating Vascular Disease	08/05/04
U.S.	6,239,172	Formulations for Treating Disease and Methods of Using Same	01/07/99
PCT	PCT/US00/00399	Formulations for Treating Disease and Methods of Using Same	01/07/00
Canada	2358212	Formulations for Treating Disease and Methods of Using Same	01/07/00
EP	00904248.2	Formulations for Treating Disease and Methods of Using Same	01/07/00
Japan	2000-591860	Formulations for Treating Disease and Methods of Using Same	01/07/00
Mexico	2001/006926	Formulations for Treating Disease and Methods of Using Same	01/07/00
U.S.	6,425,881	Therapeutic Mixture Useful in Inhibiting Lesion Formation After Vascular Injury	04/16/99
U.S.	10/207,399	Therapeutic Mixture Useful in Inhibiting Lesion Formation After Vascular Injury	07/29/02
U.S.	10/763,309	Pharmaceutical Composition Comprising Citrulline	01/23/04
PCT	PCT/US00/10298	Therapeutic Mixture Useful in Inhibiting Lesion Formation After Vascular Injury	07/29/02
Canada	2369772	Therapeutic Mixture Useful in Inhibiting Lesion Formation After Vascular Injury	07/29/02
EP	00922275.3	Therapeutic Mixture Useful in Inhibiting Lesion Formation After Vascular Injury	07/29/02
Mexico	231874	Therapeutic Mixture Useful in Inhibiting Lesion Formation After Vascular Injury	07/29/02
U.S.	09/420,816	A Therapeutic Mixture of HMG-CoA	10/19/99

		reductase Inhibitors	
U.S.	10/269,847	A Therapeutic Mixture of HMG-CoA reductase Inhibitors	10/11/22
PCT	PCT/US00/41304	A Therapeutic Mixture of HMG-CoA reductase Inhibitors	10/19/00
Canada	2388530	A Therapeutic Mixture of HMG-CoA reductase Inhibitors	10/19/00
EP	00984562.9	A Therapeutic Mixture of HMG-CoA reductase Inhibitors	10/19/00
Mexico	02/004021	A Therapeutic Mixture of HMG-CoA reductase Inhibitors	10/19/00
U.S.	60/118,903	L-Arginine Based Formulations for Treating Disease and Methods of Using Same	02/05/99
U.S.	09/497,721	L-Arginine Based Formulations for Treating Disease and Methods of Using Same	02/04/00
PCT	PCT/US00/02798	L-Arginine Based Formulations for Treating Disease and Methods of Using Same	02/04/00
Canada	2361575	L-Arginine Based Formulations for Treating Disease and Methods of Using Same	02/04/00
EP	00911701.1	L-Arginine Based Formulations for Treating Disease and Methods of Using Same	02/04/00
EP	06007096.8	L-Arginine Based Formulations for Treating Disease and Methods of Using Same	02/04/00
Japan	2000-596929	L-Arginine Based Formulations for Treating Disease and Methods of Using Same	02/04/00
Mexico	2001/007952	L-Arginine Based Formulations for Treating Disease and Methods of Using Same	02/04/00
U.S.	09/605,559	Controlled Release Arginine Formulations	06/28/00
U.S.	10/258,633	Controlled Release Arginine Formulations	06/28/01
PCT	PCT/US0120887	Controlled Release Arginine Formulations	06/28/01
Canada	2413816	Controlled Release Arginine Formulations	06/28/01
EP	01950733.4	Controlled Release Arginine Formulations	06/28/01
Japan	2002-504944	Controlled Release Arginine Formulations	06/28/01
Mexico	2003/000194	Controlled Release Arginine Formulations	06/28/01